GlaxoSmithKline Discontinues Development Of Remogliflozin
Discontinuation as a result of evaluating circumstances, including the development status of SGLT2 inhibitors by competitors
Kissei Pharmaceutical announced that GlaxoSmithKline has discontinued the development of the novel agent for diabetes, remogliflozin (KGT-1681). It was as a result of evaluating circumstances including the development status of SGLT2 inhibitors by competitors.
Kissei has discovered the SGLT2 inhibitor, remogliflozin and the SGLT1 inhibitor, KGA-3235 for diabetes, and licensed the development and marketing right of the agents in the US and Europe to GlaxoSmithKline.
Remogliflozin is in the stage of phase-II clinical studies, whereas KGA-3235 is in the stage of phase-I clinical study.
With regard to the development of SGLT inhibitors, GlaxoSmithKline has decided to continue to develop KGA-3235.
Related Insight
Suppliers Directory
Pittcon - Conference and Exposition for Laboratory Science
Pittcon is the world’s largest annual conference and exposition for laboratory science offering the latest technology and instrumentation from 1,000 exhibitors from more than 90 countries, unique networking opportunities, a diverse technical program of over 2,000 sessions, and over 100 short courses to enhance your educational experience at Pittcon.
Suppliers
TBM Consulting Group - Lean Sigma Manufacturing Services
The global fallout from the real estate and banking crisis has impacted economies worldwide since 2009 and is likely to carry over well into 2012. The drop in consumer demand, capital spending cuts, layoffs, rising unemployment, the spectre of inflation and erratic equity markets has put intense pressure on margins and heightened everyone’s focus on cutting costs.
Suppliers
Vaisala - Measurement Instruments and Continuous Monitoring System for Critical Environments in Life Science and High-Technology
Vaisala is a global leader in environmental and industrial measurement.
Suppliers
Rapid Micro Biosystems - Save Time, Save Money, Increase Productivity
Rapid Micro Biosystems provides innovative products for faster detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
DXA Services
Published by CoreLab Partners
White Papers
Sample Preparation in Wildlife Forensics
Published by Genevac
White Papers
Tips & Tricks - GPC/SEC: Copolymer Analysis in GPC/SEC 3 - Polymer Liquid Adsorption Chromatography
Published by Polymer Standards Service
White Papers
Polymeric Nanofibers, Nanofibrous Layers, Nanofiber Yarns and Nanoparticles
Published by Phenom World
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.